Literature DB >> 7905794

Inhibition of CD4+ T lymphocyte binding to fibronectin and immune-cell accumulation in inflammatory sites by non-peptidic mimetics of Arg-Gly-Asp.

R Hershkoviz1, N Greenspoon, Y A Mekori, R Hadari, R Alon, G Kapustina, O Lider.   

Abstract

The Arg-Gly-Asp (RGD) cell adhesion motif has been demonstrated in various studies to play a pivotal role in leucocyte and platelet interactions with plasma and extracellular matrix (ECM) glycoproteins. The recognition of the RGD sequence is mediated by heterodimeric receptors designated integrins of the beta 1 subfamily, expressed on distinct cell types, including T lymphocytes. We have recently shown that flexible non-peptidic mimetics of RGD, in which the two ionic side groups were separated by a linear spacer of 11 atoms, bound specifically to the platelet integrin alpha 11b beta 3, and inhibited T cell-mediated immune responses. The present study was designed to (i) further characterize the structural requirements for RGD interactions with CD4+ T cells, and (ii) examine the mechanisms by which the RGD mimetics interfere with immune cell reactivity in vivo. We now report that freezing the conformational degrees of freedom in the spacer chain, which fixes the relative orientation of the guanidinium and carboxylate side groups in a favourable manner, results in a higher level of inhibition of T cell binding to immobilized fibronectin, an RGD-containing ECM glycoprotein. In vivo, treatment of mice with relatively low doses of the RGD mimetics, but not the RGD peptide, inhibited the elicitation of an adoptively transferred DTH reaction. This inhibition was achieved by direct impairment of the ability of antigen-primed lymph node cells to migrate and accumulate in inflammatory sites. Hence, we suggest that the design and production of non-peptidic mimetics of RGD offers a novel approach to study defined parameters related to the structure-function requirements of small adhesion epitopes. Furthermore, this approach could be used therapeutically to inhibit pathological processes which depend on RGD recognition.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7905794      PMCID: PMC1534914          DOI: 10.1111/j.1365-2249.1994.tb06522.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

Review 1.  Integrins: versatility, modulation, and signaling in cell adhesion.

Authors:  R O Hynes
Journal:  Cell       Date:  1992-04-03       Impact factor: 41.582

Review 2.  Lymphocyte interactions with extracellular matrix.

Authors:  Y Shimizu; S Shaw
Journal:  FASEB J       Date:  1991-06       Impact factor: 5.191

Review 3.  Adhesion receptors of the immune system.

Authors:  T A Springer
Journal:  Nature       Date:  1990-08-02       Impact factor: 49.962

4.  Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity.

Authors:  O Lider; Y A Mekori; T Miller; R Bar-Tana; I Vlodavsky; E Baharav; I R Cohen; Y Naparstek
Journal:  Eur J Immunol       Date:  1990-03       Impact factor: 5.532

5.  Regulated expression and binding of three VLA (beta 1) integrin receptors on T cells.

Authors:  Y Shimizu; G A Van Seventer; K J Horgan; S Shaw
Journal:  Nature       Date:  1990-05-17       Impact factor: 49.962

Review 6.  Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif.

Authors:  S E D'Souza; M H Ginsberg; E F Plow
Journal:  Trends Biochem Sci       Date:  1991-07       Impact factor: 13.807

7.  Streptavidin blocks immune reactions mediated by fibronectin-VLA-5 recognition through an Arg-Gly-Asp mimicking site.

Authors:  R Alon; R Hershkoviz; E A Bayer; M Wilchek; O Lider
Journal:  Eur J Immunol       Date:  1993-04       Impact factor: 5.532

8.  Role of the alpha v beta 3 integrin in human melanoma cell invasion.

Authors:  R E Seftor; E A Seftor; K R Gehlsen; W G Stetler-Stevenson; P D Brown; E Ruoslahti; M J Hendrix
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

9.  Two integrin-binding peptides abrogate T cell-mediated immune responses in vivo.

Authors:  T A Ferguson; H Mizutani; T S Kupper
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

10.  Monoclonal antibody characterization of two distant sites required for function of the central cell-binding domain of fibronectin in cell adhesion, cell migration, and matrix assembly.

Authors:  T Nagai; N Yamakawa; S Aota; S S Yamada; S K Akiyama; K Olden; K M Yamada
Journal:  J Cell Biol       Date:  1991-09       Impact factor: 10.539

View more
  5 in total

Review 1.  Pathophysiological aspects of VLA-4 interactions and possibilities for therapeutical interventions.

Authors:  T W Kuijpers
Journal:  Springer Semin Immunopathol       Date:  1995

Review 2.  VLA-4 and lymphocyte trafficking in immune-inflammatory states: novel therapeutic approaches in allograft arteriopathy.

Authors:  S Molossi; M Rabinovitch
Journal:  Springer Semin Immunopathol       Date:  1995

3.  Analysis of Arg-Gly-Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A induced hepatitis in mice.

Authors:  R Bruck; H Shirin; R Hershkoviz; O Lider; G Kenet; H Aeed; Z Matas; L Zaidel; Z Halpern
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

4.  Matrix valency regulates integrin-mediated lymphoid adhesion via Syk kinase.

Authors:  D G Stupack; E Li; S A Silletti; J A Kehler; R L Geahlen; K Hahn; G R Nemerow; D A Cheresh
Journal:  J Cell Biol       Date:  1999-02-22       Impact factor: 10.539

Review 5.  The use of synthetic analogues of Arg-Gly-Asp (RGD) and soluble receptor of tumor necrosis factor to prevent acute and chronic experimental liver injury.

Authors:  R Bruck; R Hershkoviz; O Lider; H Shirin; H Aeed; Z Halpern
Journal:  Yale J Biol Med       Date:  1997 Jul-Aug
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.